Onkológia 1/2017
Palbociclib in the treatment of advanced breast cancer
Breast cancer is the most prevalent cancer diagnosis in Slovakia with an increasing incidence. Despite epidemiological data showing decrease in mortality over time, metastatic disease is invariably fatal. For patients with hormonal positivity, inhibitors of cyclin dependent kinases (CDK4/6) represent a new therapeutic option. Palpociclib is only approved CDK4/6 inhibitor, yielded improved PFS of 10 months in treatment naive patients and of 5.4 months in pretreated patients with hormones or chemotherapy.
Keywords: inhibitors of cyclin dependent kinases, palbociclib, breast cancer
